Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BL1332 eye drops
BL1332 eye · 1 trial · 1 indication
NPRS scale 0 to 10, with higher score reflecting worse pain
| Arm | Type | Description |
|---|---|---|
| BL1332 eye drops | ACTIVE_COMPARATOR | - |
| BL1332 Placebo eye drops | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BL1332 eye drops | DRUG | Taken 1 time |
| BL1332 Placebo eye drops | DRUG | Taken 1 time |
Inclusion Criteria: * Male or female ≥ 18 to ≤ 65 years of age. * In good health, as assessed at Screening by the Investigator from past medical history, physical examination (abbreviated), and laboratory tests. * Does not wear contact lenses, or is willing to refrain from wearing contact lenses fo...
BL1332 eye is an investigational small molecule eye drop developed by Bausch Health Companies Inc. It is being studied in a Phase 1 clinical trial for capsaicin-induced ocular pain in healthy participants. The specific therapeutic indication has not been disclosed.
BL1332 eye drops are being developed by Bausch Health Companies Inc., which trades on the New York Stock Exchange under the ticker BHC. The company is the sponsor of the clinical program for this investigational small molecule ophthalmic product.
BL1332 eye is in Phase 1 clinical development. It is an investigational product and has not been approved by the FDA. The Phase 1 program consists of one completed trial evaluating the drug in healthy participants.
BL1332 eye has been studied in one Phase 1 trial, NCT07717918, titled A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants. The trial was completed, enrolled 28 participants, was randomized, double-blind, and placebo-controlled, and was conducted in the United States.
Yes, BL1332 eye and BL1332 eye drops refer to the same investigational product from Bausch Health Companies Inc. The eye drop formulation is the dosage form being evaluated in the Phase 1 trial NCT07717918 for capsaicin-induced ocular pain.